Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial on Palliative Cancer Patients With Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severity of constipation \> 3 points (an 8-point scale from 0 to 7)~* Palliative Performance Scale ≥60%~* Relatively stable liver and renal function within 3 months~* Patients who can read and speak Chinese~Exclusion Criteria:~* Inability to communicate~* Presence of a colostomy, or gastrointestinal obstruction~* Presence of loose or watery stool (Bristol stool scale 6-7) or bowel movement \> 3/day under routine laxative treatment~* History of Chinese herbal medicine allergies~* Estimated life expectancy less than 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chinese herbal medicine (Type: EXPERIMENTAL): MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.

Based on this trial design, predict the completion outcome and termination type (if applicable).